Revolution Medicines Stock Forecast

Stock Price Forecast

According to 25 analysts polled by S&P Global, Revolution Medicines stock has a consensus rating of "Strong Buy" and an average price target of $258.84. The average 1-year stock price forecast is 35.30% higher than the current stock price, while the lowest is $179 (-6.43%) and the highest is $320 (+67.27%).

Price Target: $258.84 (+35.30%)

Analyst Consensus: Strong Buy

Price Target

Chart

Target	Low	Average	Median	High
Price	$179	$258.84	$260	$320
Change	-6.43%	+35.30%	+35.91%	+67.27%

Analyst Ratings

The average analyst rating for Revolution Medicines stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Chart

Rating	May '26	Jun '26	Jul '26	Aug '26	Sep '26	Oct '26
Strong Buy	17	17	17	17	17	19
Buy	4	4	4	4	5	5
Hold	1	1	1	1	1	1
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	22	22	22	22	23	25

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Alec Stranahan Bank of America Securities	Bank of America Securities	Buy Maintains $264	Buy	Maintains	$264	+38.00%	Oct 26, 2026
Michael Yee UBS	UBS	Buy Reiterates $265	Buy	Reiterates	$265	+38.52%	Oct 22, 2026
Sean Laaman Morgan Stanley	Morgan Stanley	Buy Maintains $255	Buy	Maintains	$255	+33.29%	Oct 22, 2026
Tyler Van Buren TD Cowen	TD Cowen	Buy Reiterates $250	Buy	Reiterates	$250	+30.68%	Oct 21, 2026
Brian Cheng J.P. Morgan	J.P. Morgan	Buy Maintains n/a	Buy	Maintains	n/a	n/a	Oct 21, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

200.82M

Revenue Next Year

1.26B

from 200.82M

526.64%

from 200.82M

EPS This Year

-9.58

from -5.95

EPS Next Year

-5.76

from -9.58

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	29.39M	35.38M	11.58M	-	-	200.82M
Gross Profit	-157.56M	-217.69M	-407.86M	-592.23M	-987.33M	172.08M
Gross Margin	-536.09%	-615.30%	-3,522.14%	-	-	85.69%
Operating Income	-188.01M	-258.28M	-475.99M	-689.52M	-1.18B	-1.92B
Net Income	-187.09M	-248.71M	-436.37M	-600.09M	-1.13B	-2.02B
EPS	-	-	-	-	-5.95	-9.58
Free Cash Flow	-	-	-	-	-913.73M	-1.67B
No. Analysts	-	-	-	-	-	24

EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Chart

Revenue	2026	2027	2028
High	354.7M
Avg	200.8M
Low	45.1M

Revenue Growth

Chart

Revenue Growth	2027	2028
High	935.6%
Avg	526.6%
Low	206.1%

EPS Forecast

Chart

EPS	2026	2027	2028
High	-8.21
Avg	-9.58
Low	-12.17

EPS Growth

Chart

EPS Growth	2026	2027	2028
High	-
Avg	-
Low	-